1. Home
  2. DTSS vs XCUR Comparison

DTSS vs XCUR Comparison

Compare DTSS & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Datasea Inc.

DTSS

Datasea Inc.

N/A

Current Price

$0.44

Market Cap

8.2M

Sector

Technology

ML Signal

N/A

Logo Exicure Inc.

XCUR

Exicure Inc.

N/A

Current Price

$1.02

Market Cap

9.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DTSS
XCUR
Founded
2014
2011
Country
China
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.2M
9.2M
IPO Year
2026
2017

Fundamental Metrics

Financial Performance
Metric
DTSS
XCUR
Price
$0.44
$1.02
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
54.9K
★ 71.2K
Earning Date
12-01-2026
12-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 83.37
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$44.02
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.46
$0.78
52 Week High
$2.29
$9.48

Technical Indicators

Market Signals
Indicator
DTSS
XCUR
Relative Strength Index (RSI) 30.19 46.83
Support Level N/A $0.89
Resistance Level $0.77 $1.24
Average True Range (ATR) 0.05 0.11
MACD -0.01 0.02
Stochastic Oscillator 0.00 58.87

Price Performance

Historical Comparison
DTSS
XCUR

About DTSS Datasea Inc.

Datasea Intelligent Technology Ltd, formerly known as Datasea Inc, is a technology company that operates in two main segments. The first segment, Acoustic High-Tech, focuses on developing and applying acoustic technologies, such as ultrasound, infrasound, and mechanical wave effects, for applications like ultrasonic sterilization, neuro-regulation, acupoint stimulation, and environmental purification. The second segment, AI Multimodal Digitalization, integrates artificial intelligence with 5G networks and data processing to create a proprietary multimodal data platform that combines text, voice, image, and video for real-time intelligent analysis and generation. The company generates all of its revenue from the People's Republic of China (PRC) markets.

About XCUR Exicure Inc.

Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.

Share on Social Networks: